E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
|3||Active, not recruiting||
Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients
Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients
† Study has passed its completion date and status has not been verified in more than two years.